Efficacy News and Research

RSS

Researchers identify bouncer protein that plays a vital role in RA prevention

Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

8 Sep 2011

Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Boehringer Ingelheim and Eli Lilly and Company will present the latest data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16.

8 Sep 2011

Ohio Third Frontier grants to advance Philips Healthcare Global Advanced Imaging Innovation Center

The Ohio Third Frontier Commission has awarded $2.5 million in research grants to advance the Philips Healthcare Global Advanced Imaging Innovation Center, a collaboration among Case Western Reserve University, University Hospitals (UH) Case Medical Center and Philips Healthcare. The research projects are part of $30 million in funding awarded throughout the State of Ohio this week by the Ohio Third Frontier Commission.

8 Sep 2011

Access to health insurance top indicator for better outcomes among undocumented children

Undocumented children who have access to health insurance are healthier and more engaged in school than those without insurance, according to researchers at the Keck School of Medicine of the University of Southern California.

8 Sep 2011

Beta-glucans can help wounds to heal quickly

Can wounds be helped to heal faster? Yes, says a Norwegian company whose product's active ingredient, beta-glucans, comes from common baker's yeast.

8 Sep 2011

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Teva Pharmaceutical Industries Ltd. and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD).

7 Sep 2011

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.

7 Sep 2011

Researchers rethink fenretinide for prevention of oral cancer

Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.

7 Sep 2011

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.

7 Sep 2011

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.

7 Sep 2011

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

International researchers to assess role of pre-clinical animal models in drug discovery

The New York Academy of Sciences and the Global Medical Excellence Cluster (GMEC), in collaboration with Imperial College London and King's College London, will host a two-day scientific conference, "Animal Models and Their Value in Predicting Drug Efficacy and Toxicity," that will provide a forum to critically examine the role of pre-clinical animal models in drug discovery.

7 Sep 2011

New bone marrow-derived stem cell therapy can benefit patients with degenerative disc disease

Neurosurgery researchers at UC Davis Health System have used a new, leading-edge stem cell therapy to promote the growth of bone tissue following the removal of cervical discs -- the cushions between the bones in the neck -- to relieve chronic, debilitating pain.

7 Sep 2011

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Computer-tailored nutrition education not effective in reducing fat intake

As lifestyles get busier and waistlines get bigger; many people are turning to online nutrition programs. In promotion of healthful nutrition behaviors, computer-tailored nutrition education has been identified as a promising health education strategy, especially in the promotion of lower fat intake.

7 Sep 2011

IOF presents eight young investigator awards to researchers across the world

Eight IOF Young Investigator Awards were presented by the International Osteoporosis Foundation (IOF) to young researchers from Australia, China, India and Japan, in recognition of their outstanding work. The awards, valued at 1,000 USD each, were awarded to the highest scored abstracts by researchers under the age of 40.

7 Sep 2011

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

Discovery Labs, Inc. today announced that, on September 2, 2011, it submitted its Complete Response to the 2009 Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for SURFAXIN(lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants.

6 Sep 2011

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke.

6 Sep 2011

Efficacy News and Research

Researchers identify bouncer protein that plays a vital role in RA prevention

Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Ohio Third Frontier grants to advance Philips Healthcare Global Advanced Imaging Innovation Center

Access to health insurance top indicator for better outcomes among undocumented children

Beta-glucans can help wounds to heal quickly

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Researchers rethink fenretinide for prevention of oral cancer

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

International researchers to assess role of pre-clinical animal models in drug discovery

New bone marrow-derived stem cell therapy can benefit patients with degenerative disc disease

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Computer-tailored nutrition education not effective in reducing fat intake

IOF presents eight young investigator awards to researchers across the world

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News